Investors

Our start-up and equity portfolio secures funding from investors around the world who believe in our world-class science and the power of partnership.

We offer investment opportunities in new therapeutics, diagnostics, medical devices and data-driven and AI solutions.

Investors image

79

start-ups formed to date

23

exits to date

£3bn

raised by our portfolio to date

What we offer

Seed investmentStart-up supportScientific expertiseExpert network
Our Seed Fund has provided early-stage funding to 22 exciting new ventures so far, and our portfolio continues to grow with several ground breaking opportunities in stealth.Our expert teams guide researchers in developing their promising discoveries - from entrepreneurial training, advice and funding through to seed investment and commercial support for company formation and scaling up.We leverage our drug discovery and development expertise in partnerships with researchers and industry to identify and advance novel approaches with the potential to deliver the next generation of cancer medicines. We have unparalleled access to a global network of researchers, clinicians and partners allowing us to call on world-leading experts to validate translational potential and inform our investment decisions.
A man and woman talking at a conference.

Join our Cancer Impact Club

Investor news

Our Cancer Impact Club is a community of business builders whose philanthropy, expertise and networks will multiply our impact on early-stage cancer ventures. It comprises entrepreneurs and leaders from private equity, venture capital, and associated companies and will bring together up to 50 members to raise £5m to help double our Seed Fund’s impact.

Find out more
Two professionals standing side by side and engaged in discussion. They are both holding grey cups and smiling.

Our Investor Networking Breakfast series

These invite-only events showcase innovative companies from across our start-up portfolio that are reaching major milestones towards patient impact, bringing together like-minded oncology investors and innovators for networking and insights.

Get in touch with our team to learn when our next Investor Networking Breakfast is taking place. 

Contact us
Three people in discussion sat at a table

Our start-up portfolio

We've built an incredible assembly line for start-up companies to bring early-stage technologies out of the research lab and translate them into patient benefit.

To date, we've played a role in the creation of 79 start-ups, with our portfolio of existing companies raising in excess of £3bn in total capital.

View our start-up portfolio
Image of Phil Masterson

Ventures team

Our Ventures team have a long-standing track record of sourcing, evaluating and creating start-ups. They manage the Seed Fund work alongside an independent investment committee to review applications.

Meet the Ventures team
Akamis Bio logo

Akamis Bio announces enrollment of first patient in Phase 1b FORTRESS trial

Portfolio news

Portfolio company Akamis Bio has enrolled its first patient in Phase 1b of their FORTRESS Trial of NG-350A, a next generation, systemically administered immunotherapy designed to drive intratumoral expression of a CD40 agonist monoclonal antibody in both primary and metastatic tumor sites in patients with locally advanced rectal cancer.

Learn more
Group of investors in discussion at an event

How we partner with investors

We're keen to connect with seed and series A-focused funds to create and grow new companies offering unique early-stage investment opportunities.

Our Seed Fund investments are catalytic, with Cancer Research Horizons considered a validating investor by like-minded early-stage investors.  An important impact measure for the fund is to leverage third-party capital alongside our own investments.  

Start a conversation with the Ventures team
Two men stand in a library setting. The man on the left wears a blue checked blazer, while the man on the right wears glasses and a dark jacket. Both have lanyards. Bookshelves are visible in the background.

Join our expert network

Our world-class expert network, drawn from our extensive research community and partners, comprises leading business, scientific, clinical, investment, and industry experts across the oncology sector.

Their unrivalled experience and expertise help empower our researchers and founding teams, and maximise the success of our venture, licensing, and partnership opportunities. 

Learn more
A man wearing glasses and a blue blazer sits at a booth, deep in conversation with someone off-frame. He wears a lanyard with the Cancer Research Horizons logo on it.

The cutting-edge of translational oncology - directly to your inbox

Sign up to our newsletter

Receive quarterly updates featuring expert insights on emerging trends and thought leadership from those shaping the future of oncology innovation, specifically hand-picked by our team.  

You’ll also get the latest on our work in drug discovery, clinical trials, licensing, partnerships, and investment – all in a clear, digestible format. 

Sign up here

Upcoming events in our network

Interested in investing in world-leading cancer research?

We're seeking investors and co-investors across our portfolio.

Contact the Ventures Team